Alferminogene tadenovec

Drug Profile

Alferminogene tadenovec

Alternative Names: Ad5-FGF4; AdFGF-4; AGT-MI; Angiogenic gene therapy; Cardionovo; FGF-4 angiogenic DNA - Taxus Cardium Pharmaceuticals; FGF-4 gene therapy; Fibroblast growth factor-4 gene therapy - Taxus Cardium Pharmaceuticals; Generx; Generx microvascular therapy; mdFGF-4; mdFGF-4 - Taxus Cardium Pharmaceuticals

Latest Information Update: 10 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cardium Therapeutics
  • Developer Angionetics; Taxus Cardium Pharmaceuticals Group
  • Class Gene therapies; Growth factors; Ischaemic heart disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Coronary artery disease; Myocardial ischaemia
  • Discontinued Heart failure

Most Recent Events

  • 07 Feb 2017 Alferminogene tadenovec receives Fast Track designation for Coronary artery disease [Intracoronary,Infusion] in USA
  • 12 Sep 2016 The U.S. FDA Center for Biologics Evaluation and Research approves alferminogene tadenovec for the phase III AFFIRM study in Coronary artery disease and Myocardial ischaemia
  • 11 Jul 2016 Alferminogene tadenovec licensed to an affiliated entity of Huapont Life Sciences in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top